Rubeola Virus Immunomodulator

Company: Eudaemonic

This product license is conditional.

Efficacy and potency test studies in progress.

Composition

An inactivated rubeola virus combined with histamine phosphate in physiological saline. Contains phenol as a preservative.

GENERAL INFORMATION: RVI acts to modify the immune and inflammatory responses to alleviate Chronic Myofascial Inflammation and its associated problems in the equine.

Discussion: T-lymphocytes, including suppressor T-cells, significantly modulate the immune response. Unfortunately these cells are very sensitive to insult, whether from stress, dietary changes, infection, or environmental toxins. These suppressor T-cells function by controlling B-cells (the antibody producers), cytotoxic cells, and helper T-cells from over-responding to insults. Unless controlled, this over response could result in an immune response to auto or self antigens. Evidence indicates an auto immune component to chronic myofascial inflammation and myositis. Studies reflect a decrease in suppressor T-cell function, although not necessarily a decrease in absolute number of T-cells. RVI acts by specifically modulating suppressor T-cell function in a controlled fashion to allow re-establishment of the normal balance between various subpopulations of T- and B-lymphocytes. This will aid in the healing process leading to the decrease or elimination of myofascial inflammation in the affected animals.

Rubeola Virus Immunomodulator Indications

For treatment of Chronic Myofascial Inflammation (Myosins) in the equine.

ADMINISTRATION AND DOSAGE: Inject 2 ml. subcutaneously in neck of horse daily regardless of weight or age for three to six days or until the desired clinical condition is observed. In severe cases, daily injection may be required until the horse recovers. Maintenance doses and frequency will depend on the individual animal but may vary from one dose every other day to one dose a week or even every two weeks. CARE SHOULD BE EXERCISED TO ENSURE THAT THE INJECTION IS DELIVERED SUBCUTANEOUSLY.

Each 2 ml. dose contains 0.1 mcg. of neomycin.

Rubeola Virus Immunomodulator Caution

Store at 2° - 7° C (35° - 45° F). Protect from freezing. Contains phenol as a preservative. Rare transient local reactions may occur at the injection site but should subside within 24 hours. NOT FOR USE IN HORSES INTENDED FOR FOOD.

*Also referred to as RVI.

REFERENCES

1. Michael B. Mathews and Robert M. Bernstein (1983) Myositis autoantibody inhibits histidyl-tRNA synthetase: a model for autoimmunity, Nature, Vol. 304. p. 177-179.

2. F.W. Miller, L.A. Love, B.A. Barbieri, S.E. Balow, and P.H. Plotz. (1990) Lymphocyte activation markers in idiopathic myostitis; changes with disease activity and differences among clinical and autoantibody subgroups. Clin. Exp. lmmunol. Vol. 81, p. 373-379.

How Supplied

12 x 12 ml. six dose vials.

U. S. Veterinary License No. 385

EUDAEMONIC CORPORATION, 7031 No. 16th Street, Omaha, Nebraska 68112

CPN: 1404001.1